Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca and Bristol-Myers Squibb announces U.S. FDA Approval of Farxiga (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes


Monday, 13 Jan 2014 02:30am EST 

AstraZeneca PLC and Bristol-Myers Squibb Company:Says U.S. Food and Drug Administration (FDA) approved Farxiga [far-SEE-ga] (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Says Farxiga should not be used for the treatment of patients with type 1 diabetes or diabetic ketoacidosis. 

Company Quote

73.64
-0.14 -0.19%
3:02pm EDT